Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.

Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, D'Haens G, Mitchev K, Ernault É, Vermeire S, Brixi-Benmansour H, Moreels TG, Mary JY, Marteau P, Colombel JF.

Gut. 2013 Feb;62(2):201-8. doi: 10.1136/gutjnl-2012-302262.

2.

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):423-31.e1. doi: 10.1016/j.cgh.2013.10.025.

PMID:
24184736
3.

Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.

Ordás I, Rimola J, Rodríguez S, Paredes JM, Martínez-Pérez MJ, Blanc E, Arévalo JA, Aduna M, Andreu M, Radosevic A, Ramírez-Morros AM, Pinó S, Gallego M, Jauregui-Amezaga A, Ricart E, Panés J.

Gastroenterology. 2014 Feb;146(2):374-82.e1. doi: 10.1053/j.gastro.2013.10.055.

PMID:
24177375
4.

Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.

Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ; International Organization for the Study of Inflammatory Bowel Diseases..

Gastroenterology. 2013 Nov;145(5):978-986.e5. doi: 10.1053/j.gastro.2013.08.010.

PMID:
23954314
5.

Maintenance therapy with certolizumab pegol for Crohn's disease.

Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators..

N Engl J Med. 2007 Jul 19;357(3):239-50. Erratum in: N Engl J Med. 2007 Sep 27;357(13):1357.

6.

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.

Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P.

Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021.

PMID:
20451663
7.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
8.

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.

Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H.

Ann Rheum Dis. 2015 May;74(5):843-50. doi: 10.1136/annrheumdis-2013-204632.

9.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet..

Inflamm Bowel Dis. 2010 Jun;16(6):933-8. doi: 10.1002/ibd.21127.

PMID:
20014021
10.

Certolizumab pegol for the treatment of Crohn's disease.

Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators..

N Engl J Med. 2007 Jul 19;357(3):228-38.

11.

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.

Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR.

Aliment Pharmacol Ther. 2014 Oct;40(8):903-16. doi: 10.1111/apt.12930.

12.

Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.

Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators..

Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014.

PMID:
20117244
13.

Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.

Augustine JM, Lee JK, Armstrong EP.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):599-609. doi: 10.1586/14737167.2014.957680. Review.

PMID:
25209304
14.

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.

Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.

Aliment Pharmacol Ther. 2010 Jun;31(12):1276-85. doi: 10.1111/j.1365-2036.2010.04303.x.

15.

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.

Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators..

Am J Gastroenterol. 2010 Jul;105(7):1574-82. doi: 10.1038/ajg.2010.78.

PMID:
20234346
16.

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.

Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet..

Inflamm Bowel Dis. 2011 Jul;17(7):1530-9. doi: 10.1002/ibd.21521.

PMID:
21674709
17.

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.

Sieper J, Landewé R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP.

Arthritis Rheumatol. 2015 Mar;67(3):668-77. doi: 10.1002/art.38973.

18.

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.

Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ.

Aliment Pharmacol Ther. 2010 Aug;32(3):384-93. doi: 10.1111/j.1365-2036.2010.04360.x.

19.

Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.

Tun GS, Lobo AJ.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):317-27. doi: 10.1517/17425255.2015.995166. Review.

PMID:
25586216
20.

Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.

Feagan BG, Hanauer SB, Coteur G, Schreiber S.

Aliment Pharmacol Ther. 2011 May;33(10):1143-51. doi: 10.1111/j.1365-2036.2011.04636.x.

Supplemental Content

Support Center